Cannabis Stock Surges on Trump’s Surprise CBD Endorsement

Tilray shares experienced significant volatility this week following unexpected comments from Donald Trump advocating CBD use for senior health. The cannabis company’s stock skyrocketed 31.3% after the former president posted a video on his Truth Social platform promoting cannabidiol benefits.

Market Reacts to Political Shift

In a nearly three-minute video presentation, Trump highlighted CBD’s potential advantages for elderly patients dealing with sleep disorders, stress management, and pain treatment. He described the compound as potentially “the most important senior health initiative of this century” and suggested possible future Medicare coverage for such treatments.

This political endorsement represents a potential turning point for federal cannabis policy. The video presentation indicated that full integration of cannabis into medical treatment protocols could generate approximately $64 billion in healthcare system savings.

Sector Demonstrates Regulatory Sensitivity

The dramatic share price movement underscores the cannabis industry’s continued dependence on political and regulatory developments:

• 31.3% surge following Trump’s CBD endorsement
• 300% returns since July 2025
• 41.4% single-day jump on September 29
• 52-week high reached at $1.85

Tilray currently trades near multi-month peaks, reflecting renewed investor confidence surrounding potential cannabis reform measures.

Should investors sell immediately? Or is it worth buying Tilray?

Quarterly Results Loom

Investors face a crucial test on October 9 when Tilray discloses first-quarter financial results for fiscal year 2026. Market experts anticipate:

• Projected EPS: -$0.03 (representing 25% year-over-year improvement)
• Revenue forecast: $206.83 million (3.39% increase)
• Annual revenue projection: $877.28 million (6.81% growth)

These figures will determine whether recent politically-driven gains reflect fundamental business improvement or speculative enthusiasm.

Strategic Expansion Beyond Core Business

Tilray has deliberately diversified operations beyond traditional cannabis activities, establishing itself among America’s largest craft beverage producers. The company has acquired more than a dozen beer and spirits brands while forming partnerships with industry leaders including Anheuser-Busch and Molson Coors.

Additionally, Tilray has entered the hemp-based THC beverage market across multiple states with brands like Liquid Love and Happy Flower. International operations, particularly in Germany and Italy, delivered 19% revenue growth during fiscal year 2025.

Regulatory Reform Remains Critical

Potential rescheduling from Schedule 1 to Schedule 3 classification would eliminate burdensome 280E tax provisions that currently constrain cannabis company profitability. Trump previously suggested in August that a rescheduling decision would emerge within weeks, though concrete action has yet to materialize.

The stock’s extreme volatility—with 75 separate moves exceeding 5% during the past year—highlights the speculative nature of cannabis investments. Tilray’s central challenge remains converting political momentum into sustainable business growth.